Soleno Therapeutics (SLNO) EBITDA (2013 - 2026)
Soleno Therapeutics (SLNO) reported EBITDA of $29.1 million for Q1 2026, up 166.33% year-over-year from $10.9 million in Q1 2025, and down 32.91% quarter-over-quarter from $43.4 million in Q4 2025.
Soleno Therapeutics (SLNO) EBITDA (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 14 years of EBITDA data on file, last reported at $29.1 million in Q1 2026.
- EBITDA for Q1 2026 came in at $29.1 million, up 166.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $94.0 million (up 147.49% YoY), and the FY2025 annual result was $20.9 million, up 111.93% from the prior year.
- EBITDA eased to $29.1 million in Q1 2026 per SLNO's latest filing, from $43.4 million in the prior quarter.
- Over five years, EBITDA peaked at $43.4 million in Q4 2025 and troughed at -$75.6 million in Q3 2024.
- A 5-year average of -$11.1 million and a median of -$8.3 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2024 and 2025: EBITDA sank 595.71% in 2024, then soared 176.82% in 2025.
- A 5-year view of EBITDA shows it stood at -$5.5 million in 2022, then tumbled by 105.96% to -$11.3 million in 2023, then tumbled by 400.36% to -$56.5 million in 2024, then soared by 176.82% to $43.4 million in 2025, then slumped by 32.91% to $29.1 million in 2026.
- Business Quant data shows SLNO's EBITDA at $29.1 million in Q1 2026, $43.4 million in Q4 2025, and $26.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 29.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.13 Mn |
| Dec 31, 2025 | 43.41 Mn |
| Sep 30, 2025 | 26.29 Mn |
| Jun 30, 2025 | -4.85 Mn |
| Mar 31, 2025 | -43.91 Mn |
| Dec 31, 2024 | -56.52 Mn |
| Sep 30, 2024 | -75.57 Mn |
| Jun 30, 2024 | -21.90 Mn |
| Mar 31, 2024 | -21.50 Mn |
| Dec 31, 2023 | -11.30 Mn |
| Sep 30, 2023 | -10.86 Mn |
| Jun 30, 2023 | -8.49 Mn |
| Mar 31, 2023 | -8.34 Mn |
| Dec 31, 2022 | -5.48 Mn |
| Sep 30, 2022 | -6.13 Mn |
| Jun 30, 2022 | -6.72 Mn |
| Mar 31, 2022 | -5.73 Mn |
| Dec 31, 2021 | -3.00 Mn |
| Sep 30, 2021 | -8.14 Mn |
| Jun 30, 2021 | -10.99 Mn |